
Nektar Therapeutics’ Wider-than-Expected Q4 Loss: Focus Shifts to Pipeline Progress Amid Stock Rebound
Nektar Therapeutics’ Fourth-Quarter Earnings: A Review Nektar Therapeutics (NKTR), a clinical-stage biotech company, recently reported its fourth-quarter earnings for 2021. The financial results fell short of analysts’ estimates, with earnings per share coming in at a loss of $1.08 versus the predicted loss of $0.82 per share. Revenues also missed the mark, amounting to $10.9…